Takeda and Innovent Biologics forge global partnership to advance oncology medicines for solid tumors
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Expanding US operations to address the increased demand for API development and manufacturing
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Subscribe To Our Newsletter & Stay Updated